End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.25 TWD | +1.79% | 0.00% | -58.87% |
Apr. 18 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Sales 2022 | 634M 19.62M | Sales 2023 | 649M 20.08M | Capitalization | 4.1B 127M |
---|---|---|---|---|---|
Net income 2022 | 47M 1.45M | Net income 2023 | - 0 | EV / Sales 2022 | 8.97 x |
Net Debt 2022 | 119M 3.68M | Net Debt 2023 | 160M 4.95M | EV / Sales 2023 | 6.56 x |
P/E ratio 2022 |
116
x | P/E ratio 2023 |
5,009
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 27.77% |
1 day | +1.79% | ||
Current month | +0.71% | ||
1 month | +2.52% | ||
3 months | -55.12% | ||
6 months | -54.03% | ||
Current year | -58.87% |
Managers | Title | Age | Since |
---|---|---|---|
Chi Hsiang Chen
CEO | Chief Executive Officer | - | 18-10-02 |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 16-04-10 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 15-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chi Hsiang Chen
CEO | Chief Executive Officer | - | 18-10-02 |
Ping-Ho Yan
BRD | Director/Board Member | - | - |
Pai Feng Wu
PRN | Corporate Officer/Principal | - | 14-07-30 |
1st Jan change | Capi. | |
---|---|---|
-58.87% | 52.31M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.13% | 238B | |
+7.01% | 204B | |
-6.50% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- 6562 Stock